Recurrence  >>  Rencarex (girentuximab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rencarex (girentuximab) / Heidelberg Pharma, Esteve, Merck (MSD)
NCT00087022 / 2004-000353-38: Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

Completed
3
864
Canada, US, RoW
girentuximab, Rencarex®, cG250 and WX-G250, placebo
Heidelberg Pharma AG
Kidney Cancer
10/12
10/12

Download Options